TY - JOUR A1 - Güntzel, Paul A1 - Schilling, Klaus A1 - Hanio, Simon A1 - Schlauersbach, Jonas A1 - Schollmayer, Curd A1 - Meinel, Lorenz A1 - Holzgrabe, Ulrike T1 - Bioinspired Ion Pairs Transforming Papaverine into a Protic Ionic Liquid and Salts JF - ACS Omega N2 - Microbial, mammalian, and plant cells produce and contain secondary metabolites, which typically are soluble in water to prevent cell damage by crystallization. The formation of ion pairs, for example, with carboxylic acids or mineral acids, is a natural blueprint to maintain basic metabolites in solution. Here, we aim at showing whether the mostly large carboxylates form soluble protic ionic liquids (PILs) with the basic natural product papaverine resulting in enhanced aqueous solubility. The obtained PILs were characterized by H-1-N-15 HMBC nuclear magnetic resonance (NMR) and in the solid state using X-ray powder diffraction, differential scanning calorimetry, and dissolution measurements. Furthermore, their supramolecular pattern in aqueous solution was studied by means of potentiometric and photometrical solubility, NMR aggregation assay, dynamic light scattering, zeta potential, and viscosity measurements. Thereby, we identified the naturally occurring carboxylic acids, citric acid, malic acid, and tartaric acid, as being appropriate counterions for papaverine and which will facilitate the formation of PILs with their beneficial characteristics, like the improved dissolution rate and enhanced apparent solubility. KW - solubility KW - transport KW - strategy KW - drugs KW - forms KW - acids Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-230265 VL - 5 IS - 30 ER - TY - JOUR A1 - Pimentel-Elardo, Sheila M. A1 - Buback, Verena A1 - Gulder, Tobias A. M. A1 - Bugni, Tim S. A1 - Reppart, Jason A1 - Bringmann, Gerhard A1 - Ireland, Chris M. A1 - Schirmeister, Tanja A1 - Hentschel, Ute T1 - New Tetromycin Derivatives with Anti-Trypanosomal and Protease Inhibitory Activities JF - Marine drugs N2 - Four new tetromycin derivatives, tetromycins 1-4 and a previously known one, tetromycin B (5) were isolated from Streptomyces axinellae Pol001(T) cultivated from the Mediterranean sponge Axinella polypoides. Structures were assigned using extensive 1D and 2D NMR spectroscopy as well as HRESIMS analysis. The compounds were tested for antiparasitic activities against Leishmania major and Trypanosoma brucei, and for protease inhibition against several cysteine proteases such as falcipain, rhodesain, cathepsin L, cathepsin B, and viral proteases SARS-CoV M(pro), and PL(pro). The compounds showed antiparasitic activities against T. brucei and time-dependent inhibition of cathepsin L-like proteases with K(i) values in the low micromolar range. KW - cysteine protease KW - drugs KW - streptomyces KW - discovery KW - anti-trypanosomal KW - protease inhibition KW - Streptomyces axinellae KW - marine sponge KW - tetromycin Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-141171 VL - 9 IS - 10 ER - TY - JOUR A1 - Worku, Netsanet A1 - Stich, August A1 - Daugschies, Arwid A1 - Wenzel, Iris A1 - Kurz, Randy A1 - Thieme, Rene A1 - Kurz, Susanne A1 - Birkenmeier, Gerd T1 - Ethyl Pyruvate Emerges as a Safe and Fast Acting Agent against Trypanosoma brucei by Targeting Pyruvate Kinase Activity JF - PLoS ONE N2 - Background Human African Trypanosomiasis (HAT) also called sleeping sickness is an infectious disease in humans caused by an extracellular protozoan parasite. The disease, if left untreated, results in 100% mortality. Currently available drugs are full of severe drawbacks and fail to escape the fast development of trypanosoma resistance. Due to similarities in cell metabolism between cancerous tumors and trypanosoma cells, some of the current registered drugs against HAT have also been tested in cancer chemotherapy. Here we demonstrate for the first time that the simple ester, ethyl pyruvate, comprises such properties. Results The current study covers the efficacy and corresponding target evaluation of ethyl pyruvate on T. brucei cell lines using a combination of biochemical techniques including cell proliferation assays, enzyme kinetics, phasecontrast microscopic video imaging and ex vivo toxicity tests. We have shown that ethyl pyruvate effectively kills trypanosomes most probably by net ATP depletion through inhibition of pyruvate kinase (Ki = 3.0\(\pm\)0.29 mM). The potential of ethyl pyruvate as a trypanocidal compound is also strengthened by its fast acting property, killing cells within three hours post exposure. This has been demonstrated using video imaging of live cells as well as concentration and time dependency experiments. Most importantly, ethyl pyruvate produces minimal side effects in human red cells and is known to easily cross the blood-brain-barrier. This makes it a promising candidate for effective treatment of the two clinical stages of sleeping sickness. Trypanosome drug-resistance tests indicate irreversible cell death and a low incidence of resistance development under experimental conditions. Conclusion Our results present ethyl pyruvate as a safe and fast acting trypanocidal compound and show that it inhibits the enzyme pyruvate kinase. Competitive inhibition of this enzyme was found to cause ATP depletion and cell death. Due to its ability to easily cross the blood-brain-barrier, ethyl pyruvate could be considered as new candidate agent to treat the hemo-lymphatic as well as neurological stages of sleeping sickness. KW - human african trypanosomiasis KW - glycolysis KW - transport KW - protein KW - cruzi KW - chemotherapy KW - metabolism KW - in vitro KW - drugs KW - sleeping sickness Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-150002 VL - 10 IS - 9 ER - TY - THES A1 - Müller, Barbara T1 - Synthese und pharmakologische Eigenschaften siliciumhaltiger Dopamin-Rezeptor-Antagonisten mit einem 4-Silapiperidin-Gerüst sowie Sigma-Liganden des 1,4´-Silaspiro[tetralin-1,4´-piperidin]-Typs T1 - Synthesis and pharmacological properties of silicon-containing dopamin receptor antagonists with a 4-silapiperidinium skeleton and sigma ligands of the 1,4´-silaspiro[tetralin-1,4´-piperidinium] type N2 - Siliciumhaltige Analoga von Loperamid und Penfluridol wurden hergestellt, Versuche zu einer alternativen Synthese von Sila-Haloperidol wurden unternommen. Siliciumhaltige Sigma-Liganden des 1,4´-Silaspiro[tetralin-1,4´-piperidin]-Typs wurden hergestellt und kristallographisch sowie pharmakologisch mit ihren Kohlenstoff-Analoga verglichen. N2 - Silicon-containing analogs of loperamide and penfluridol were synthesized, an alternative synthesis of sila-haloperidol was tried. Silicon-containing sigma ligands of the 1,4´-silaspiro[tetralin-1,4´-piperidinium] type were synthesized and their x-ray structures as well as their pharmacological properties were compared with their respective carbon analogs. KW - Loperamid KW - Haloperidol KW - Silicium KW - Silaanaloga KW - Bioisosterie KW - C/Si Bioisosterie KW - Wirkstoffe KW - C/Si bioisosteric investigations KW - drugs Y1 - 2007 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-26710 ER - TY - THES A1 - Bonkat, Gernot T1 - Einfluss von septischem Plasma und intensivmedizinischen Medikamenten auf die Zytokin- und Procalcitoninfreisetzung von in vitro stimulierten PBMC septischer Patienten und immunkompetenter Probanden T1 - About the influence of septic plasma and different drugs used in the intensiv care unit on the cytokin- and procalcitonin release from in vitro stimulated pbmc from septic patients and immuncompetent volunteers N2 - In der vorliegenden Arbeit wurde der Einfluss von verschiedenen in der Intensivtherapie der Sepsis etablierten Medikamenten auf die peripheren mononukleären Zellen gesunder Probanden und septischer Patienten untersucht. Als ein weiteres Ziel untersuchten wir, ob Plasma, das von septischen Patienten gewonnen wurde, ebenfalls eine die Mediatorproduktion der Zellen modifizierende Wirkung besitzt. Als Parameter dieser Studie dienten auf der einen Seite die proinflammatorischen Zytokine TNF-alpha, Interleukin-6 und Interferon-gamma, auf der anderen Seite Interleukin-10, dem antiinflammatorische Eigenschaften zugesprochen werden, und Procalcitonin. N2 - The present study was conducted to clarify the influence of various drugs, established in the intensiv therapie of sepsis, and septic plasma on the mediatorproduction of LPS-stimulated peripheral blood mononuclear cells isolated from healthy volunteers and septic patients. The mediators measured include TNF-alpha, IL-6, Interferon-gamma (proinflammatory cytokines), interleukin 10 (an anti-inflammatory cytokine) and procalcitonin. KW - Zytokine KW - PBMC KW - Medikamente KW - Patienten KW - Probanden KW - cytokines KW - PBMC KW - drugs KW - patients KW - probands Y1 - 2003 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-8144 ER - TY - THES A1 - Kneuer, Janine T1 - Therapie der obstruktiven Atemwegserkrankungen nach Stufenplan: Empfehlung und Realität T1 - Therapy of obstructive pulmonary disease according to the therapy plan: recommendation and reality N2 - Die vorliegende Studie beruht auf Daten von 254 Patienten, die im Zeitraum von 1990 bis 1998 stationär in die MedizinischeKlinik des Klinikums der Ludwig- Maximilians- UniversitätWürzburg eingewiesen worden sind. Die Patientengruppe bestand aus 120 Patienten mit der Entlassungsdiagnose Asthma und aus 134 Patienten mit der Entlassungsdiagnose COPD. Mittels Fragebögen wurden die Krankengeschichte sowie das aktuelle Krankheitsgeschehen erfaßt und statistisch ausgewertet. Das Hauptaugenmerk galt hierbei den verordneten Medikamenten. Als Basis diente der 1993 in einem Konsenspapier veröffentlichte Stufenplan der deutschen Atemwegsliga sowie der 1998 überarbeitete und auf die COPD Therapie erweiterte Stufenplan. In Bezug auf die Asthmatherapie stellte sich heraus, daß 55 % der Asthmapatienten zum Zeitpunkt ihrer stationären Aufnahme entsprechend des seit 1993 gültigen Stufenplanes behandelt worden sind. 32 % erhielten eine unzureichende und 10 % eine unsinnige bzw. unnötige Wirkstoffkombination. Mittels statistischer Methoden konnte eindeutig nachgewiesen werden, daß Patienten, die entsprechend des Stufenplanes behandelt worden sind, ein signifikant geringeres Risiko haben einen Status asthmaticus zu bekommen als Patienten ohne diese Therapie. Darüber hinaus hatten diese Patienten ein signifikant geringeres Rückfallrisiko. N2 - This study based on 254 in-patients, who were admitted between 1990 and 1998 into the Ludwig-Maximilian-University Hospital of Wuerzburg. This group was composed of 120 patients with the discharged diagnosis: asthma and 134 patients with the discharged diagnosis COPD. It was made an audit about the medical history and about the acute disease itself. This has been evaluated statistically. The main interest was aimed at the prescribed remedies compared with the therapy plan published in 1993 and revised in 1998 corresponding to the respective asthma stage. The result of this study was that 55% of the asthma patients were treated as demanded by the therapy plan of 1993. And 32% received an insufficient and 10% a useless medication. By means of statistical methods it was clearly proved that patients who were treate according to the therapy plan have a lower risk of being hit by a status asthmaticus than patients who were treated without this medication. And above all they have a lower recurrence risk. KW - Asthma KW - COPD KW - Stufenplan KW - Medikamente KW - asthma KW - COPD KW - therapy plan KW - drugs Y1 - 2002 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-5882 ER -